Life Sciences & Biotechnology
Title : | Disease-modifying drug combination targeting KAT-7 and HIF-2alpha formulated using active targeted dendrimer with enhanced cartilage penetration and retention for osteoarthritis treatment. |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Drug delivery system |
Principal Investigator : | Dr. Dhirendra s Katti, Indian Institute of Technology (IIT) Kanpur, Uttar Pradesh |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | dsk@iitk.ac.in |
Details
Executive Summary : | Osteoarthritis (OA) is a complex joint disorder affecting over 500 million people worldwide. Current treatments only alleviate symptoms without modifying the disease, and surgeries are associated with secondary complications. To develop disease-modifying approaches, researchers have identified KAT-7, a protein that helps the survival of senescent cells in Werner syndrome, as a potential target. They hypothesized that KAT-7 might be present in OA cartilage and used a specific inhibitor (WM-3835) to downregulate senescence in the goat OA model and human OA cartilage. A HIF2alpha-specific inhibitor (PT-2385) was also identified to downregulate other OA hallmarks. The combination of inhibitors will be studied in a goat ex vivo OA model and human OA cartilage explants to demonstrate enhanced OA mitigation. Implementation of this proposal could lead to a paradigm shift in OA disease modification. |
Co-PI: | Dr. Amitabha Bandyopadhyay, Indian Institute of Technology (IIT) Kanpur, Uttar Pradesh |
Total Budget (INR): | 69,99,880 |
Organizations involved